Houlihan Lokey Advises Peak Rock Capital
Peak Rock Capital has
acquired Asembia
Buyside Advisor
Houlihan Lokey is pleased to announce that Peak Rock Capital (Peak Rock), a private investment firm focused on the middle market, has acquired Asembia LLC and its related entities. The transaction closed on June 23, 2026.
Asembia is a leading provider of end-to-end technology-enabled commercialization solutions to the specialty pharma industry, offering a range of services for pharmaceutical manufacturers, pharmacies, patients, and prescribers, including patient support HUB services, specialty distribution, data services, pharmacy software, and group purchasing solutions. Asembia also operates the largest national specialty pharmacy conference, the Asembia Specialty Pharmacy Summit, attracting thousands of industry leaders every year.
Peak Rock is a leading private investment firm focused on the middle market that makes equity and debt investments in companies in North America and Europe. Peak Rock’s equity investment platform focuses on opportunities where it can support senior management to drive rapid growth and performance improvement, with expertise in corporate carve-outs and partnering with families and founders seeking first-time institutional capital. Peak Rock’s credit platform invests across capital structures, with a broad mandate to provide flexible, tailored capital solutions to middle-market and growth-oriented businesses. Peak Rock’s real assets platform makes equity and debt investments in small to midsized properties or assets in attractive, growing geographies.
This transaction further highlights Houlihan Lokey’s leadership across the broader pharma supply chain. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the world. In 2025, the group closed 45 transactions and was ranked by LSEG as the No. 1 advisor for all global healthcare M&A transactions.*
Houlihan Lokey served as the financial advisor to Peak Rock.
*Excludes accounting firms and brokers.
RELATED: Pharma Services, Mergers and Acquisitions